Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pemigatinibis a small molecule kinase inhibitor targeting the fibroblast growth factor receptor (FGFR), primarily for the treatment of advanced or metastatic cholangiocarcinoma cau···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：336
Pemigatinib is indicated for adult patients with advanced, metastatic, or unresectable cholangiocarcinoma with FGFR2 fusion or rearrangement confirmed by testing.What are the suita···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：327
Pemigatinib is an innovative targeted therapy that provides a new treatment option for patients with FGFR2 fusion or rearranged cholangiocarcinoma.What diseases is Pemigatinib suit···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：348
Pemigatinibis mainly used to treat specific diseases such as advanced or metastatic cholangiocarcinoma caused by FGFR2 fusion or rearrangement.What are the indications for Pemigati···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：352
Pemigatinib is used in adults to treat bile duct cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery. Pemigatinib is usually given afte···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：322
Pemigatinib is a targeted therapy drug developed by Incyte in the United States, mainly for the treatment of cholangiocarcinoma, especially in adult patients with previously treate···【more】
Article source：Captain MedicineRelease date：2024-08-12Recommended：308
Venetoclax is a drug used to treat leukemias, specifically chronic lymphocytic leukemia and acute myeloid leukemia. It effectively kills cancer cells by interfering with their surv···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：365
Venetoclax is a BCL-2 inhibitor that selectively binds to BCL-2 protein and inhibits anti-apoptotic function. This inhibition disrupts the interaction between BCL-2 and apoptosis r···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：319
Pemigatinib is a potent and selective oral antineoplastic drug targeting the FGFR subtype, primarily for the treatment of patients with advanced cholangiocarcinoma.How much is a bo···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：295
Pemigatinib is a targeted drug for cholangiocarcinoma, which has been marketed in many countries and regions around the world, and has achieved significant therapeutic effects and ···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：232
Venetoclax is a drug used to treat chronic lymphocytic leukemia (CLL) and certain types of acute myeloid leukemia (AML). It induces apoptosis in cancer cells by inhibiting the BCL-···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：353
Capmatinib is a targeted drug manufactured by Novartis for the treatment of patients with non-small cell lung cancer (NSCLC) with mutations in the MET gene. It stops the growth and···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：387
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4422025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6262024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：842026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4102025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4262025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4132025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4712025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3822025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
